• MAY 18 2017

    ONC201 Abstracts to be Presented at ASCO 2017

    Abstracts describing the recent clinical experience of ONC201 across various solid tumors will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. The first, “Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC)” will be presented in the session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

    • FEB 15 2017

    Dr. Josh Allen Presents Webinar on GPCRs With DiscoverX

    Recently, Oncoceutics’ VP of Research and Development Dr. Joshua Allen presented at a webinar hosted by DiscoverX, a leader in GPCR screening. G protein-coupled receptors (GPCRs) are the most commonly exploited drug target in modern medicine. These complex transmembrane receptors control several signaling pathways that are critical for cancer cells and are frequently hijacked by